Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients

Annals of Internal Medicine

Volumn 120, Issue 7, 1994, Pages 537-543

  Sprecher, Dennis L ^a   Abrams, Jonathan ^b   Allen, John W ^c   Keane, William F ^d   Chrysant, Steven G ^e   Ginsberg, Henry ^f   Fischer, Jerome J ^g   Johnson, Brian F ^h   Theroux, Pierre ⁱ   Jokubaitis, Leonard ^j  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b Tricore Reference Laboratory UNMH   (United States)

^c GOOD SAMARITAN HOSPITAL   (United States)

^d HENNEPIN COUNTY MEDICAL CENTER   (United States)

^e Oklahoma Cardiovascular and Hypertension Center   (United States)

^f Atherosclerosis Research Center   (United States)

^g Diabetes and Glandular Disease Research Center   (United States)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

ⁱ MONTREAL HEART INSTITUTE   (Canada)

^j Sandoz Pharma Ltd   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COLESTYRAMINE; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; FLATULENCE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; TREATMENT PLANNING;

EID: 0028209748     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-120-7-199404010-00002     Document Type: Article

References (24)

1. Illingworth DR. New horizons in combination drug therapy for hypercholesterolemia. Cardiology. 1989;76(Suppl. 1):83-100.
2. Illingworth DR, Gowan D. Management of lipoprotein abnormalities. Recent Adv Cardiol. 1987;10:71-101.
3. Illingworth DR. Lipid lowering drugs. An overview of indications and optimum therapeutic use. Drugs. 1987;33:259-79.
4. Emmerich J, Aubert I, Banduceau B, Dachet C, Chanu B, Erlich D, et al. Efficacy and safety of simvastatin (alone or in combination with cholestyramine). A 1-year study in 66 patients with type II hyperlipoproteinemia. Eur Heart J. 1990;11:149-55.
5. Superko HR, Greenland P, Manchester RA, Andreadis NA, Schectman G, West NH, et al. Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia. Am J Cardiol. 1992;70:135-40.
6. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351-64.
7. Kathawala FG. HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia. Med Res Rev. 1991;11:121-46.
8. Levy R, Troendle AJ, Fattu JM. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation. 1993;87(Suppl 3);45-53.
9. Remmell PS, Benfari RC. Assessing dietary adherence in the Multiple Risk Factor Intervention Trial (MRFIT). II. Food record rating as an indicator of compliance. J Am Diet Assoc. 1980;76:357-60.
10. Friedewald WT, Levy RI, Frederickson DS. Estimation of concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
11. Steiner PM, Freidel J, Bremner WF, Stein EA. Standardization of micromethods for plasma cholesterol, triglycerides, and HDL-cholesterol with the Lipid Research Clinics' methodology [Abstract]. J Clin Chem Biochem. 1981;19:850.
12. Lipid Research Clinics Program. Manual of Laboratory Operations. Washington, DC: U.S. Department of Health Education and Welfare; 1982; publication no.75-628.
13. Current status of blood cholesterol measurement in clinical laboratories in the United States: a report from the National Cholesterol Education Program Laboratory Standardization Panel. Clin Chem. 1988;34:193-201.
14. Mol MJ, Erkelens DW, Gevers Leuven JA, Scheuten JA, Stalenhoef AF. Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia. Atherosclerosis. 1988;69:131-7.
15. Sirtori CR, Arca M, Barone A, Bertolotto A, Carratelli L, Cattin L, et al. Clinical evaluation of simvastatin in patients with severe hypercholesterolemia. An Italian open study. Curr Ther Res. 1989; 6:230-9.
16. Da Col PG, Cattin L, Valenti M, Fisicaro M, Fergulio FS. Efficacy of simvastatin plus cholesryramine in the two-year treatment of heterozygous hypercholesterolemia. Curr Ther Res. 1990;48:798-808.
17. Mol MJ, Erkelens DW, Gevers Leuven JA, Schouten JA, Stalenhoef AF. Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia. Lancet. 1986;2:936-9.
18. Illingworth DR, Bacon SP, Larson KK. Long-term experience with HMG-CoA reductase inhibitors in the therapy of hypercholesterolemia. Atherosclerosis Rev. 1988;18:161-87.
19. Illingworth DR. Drug therapy of hypercholesterolemia. Clin Chem. 1988;34(8B):B123-32.
20. Pan HY, DeVault AR, Swites BJ, Whigan D, Ivashkiv E, Willard DA, et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther. 1990;48:201-7.
21. Vega GL, Grundy SM. Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol. JAMA. 1987;257:33-8.
22. Illingworth DR. Management of hyperlipidemia: goals for the prevention of atherosclerosis. Ciin Invest Med. 1990;13:211-8.
23. Leren TP, Hjermann I, Berg K, Leren P, Foss OP, Viksmoen L. Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia. Atherosclerosis. 1988;73:135-41.
24. Angelin B. Regulation of hepatic cholesterol metabolism in man. Ann Med. 1991:23:177-80.